Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Agomelatine is the active ingredient of these drugs:
Spain
Estonia Lithuania Poland
Poland
Germany
Estonia Lithuania Poland
South Africa
Poland
Poland
Austria Estonia Ireland Lithuania Poland
South Africa
Poland
Austria Brazil Cyprus Ecuador Estonia
South Africa
Austria Estonia Lithuania
Agomelatine is also found within below combination drugs: